Skip to content

Multi-centre Phase III clinical trial shows benefits of corticosteroid in reducing vision loss in ce

A multicenter, prospective, randomized clinical trial designed to compare 1-mg and 4-mg doses of intravitreal triamcinoclone with standard care for treatment of vision loss associated with macular edema (secondary to perfused CRVO and branch retinal vein occlusion [BRVO]) has reported the benefits of the corticosteroid injections in reducing vision